Join to View Full Profile
170 Manning DrFl 3Chapel Hill, NC 27514
Phone+1 919-966-1996
Fax+1 919-966-6735
Dr. Grover is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Education & Training
- University of North Carolina HospitalsFellowship, Hematology and Medical Oncology, 2014 - 2017
- University of Virginia Medical CenterResidency, Internal Medicine, 2011 - 2014
- Case Western Reserve University School of MedicineClass of 2011, MD
Certifications & Licensure
- NC State Medical License 2014 - 2026
- VA State Medical License 2011 - 2014
- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Assessing Physical Fitness in Cancer Patients With Cardiopulmonary Exercise Testing and Wearable Data Generation Start of enrollment: 2016 Feb 01
- Study of CAR-T Cells Expressing CD30 and CCR4 for r/r CD30+ HL and CTCL Start of enrollment: 2018 Dec 12
- Anti-CD19 CAR-T Cells With Inducible Caspase 9 Safety Switch for B-cell Lymphoma Start of enrollment: 2019 Mar 12
- Join now to see all
Publications & Presentations
PubMed
- Impact of Age on Biology, Presentation and Outcomes in Marginal Zone Lymphoma: Results From a Multicenter Cohort Study.Pallawi Torka, Natalie S Grover, Timothy J Voorhees, Reem Karmali, Kaitlin Annunzio
Hematological Oncology. 2025-05-01 - Can less differentiation drive CARs to success?Natalie S Grover, Barbara Savoldo
Blood. 2025-04-17 - Outcomes in patients with classic Hodgkin lymphoma refractory or intolerant to brentuximab vedotin and anti-PD-1 therapy: a real world analysis from 15 U.S. academic c...Timothy J Voorhees, Eric M McLaughlin, Pallawi Torka, Jorge Florindez, Na Hyun Kim
Blood Cancer Journal. 2025-03-26
Abstracts/Posters
- Retrospective Cohort Study Analyzing the Safety and Efficacy of Anti-PD-1 Therapy Following CD30 CAR-T Cell Therapy in Relapsed/Refractory Hodgkin LymphomaNatalie S Grover, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- High Risk Cytogenetic and Immunohistochemistry Findings in Monomorphic Post-Transplant Lymphoproliferative Disorder Following Solid Organ Transplant _ a Single Center ...Natalie S Grover, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Clinical Trial Participation Is Associated with Improved Overall Survival in Newly Diagnosed Patients with Mantle Cell LymphomaNatalie S Grover, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- Join now to see all
Authored Content
- AstraZeneca's Enhertu Wins Keenly-Anticipated U.S. Breast Cancer NodAugust 2022
- For Crying Out Loud: Dutch Scientists Grow Human Tear GlandsMarch 2021
Press Mentions
- What Is the Hippocampus?August 20th, 2021
- Strong Response for Tessa’s CD30 CAR-T Cell Therapy in Hodgkin’s Lymphoma TrialSeptember 9th, 2020
- CAR T Cell Therapy Makes Strides in Tackling Hodgkin LymphomaAugust 11th, 2020
- Join now to see all
Other Languages
- Russian
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence: